Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy
Zeguang Wu(Peking University), Wensheng Wei(Peking University), Catherine C. L. Wong(Chinese University of Hong Kong), Zhonghan Yang(Sun Yat-sen University), Changya Chen(Hunan University of Humanities, Science and Technology), Yuanyuan Qiu(Peking University), Lingling Yu, Feifei Liang, Zhiqiang Wu(Dali University), Jinxin Yang(Peking University), Weidong Han(Zhejiang Cancer Hospital), Yao Wang(Chinese PLA General Hospital), Yunyi Zhang(Guangzhou Medical University Cancer Hospital), Ming Jin(Peking University), Xuegang Sun(Chinese Academy of Agricultural Sciences), Qiezhong Lamao(Peking University), Huihui Yang, Haixia Zhang(University of Saskatchewan), Zhifang Li(Cotton Research Institute), Yu Sun, Yongjian Zhang(Xian Central Hospital), Liu Yang(Guilin Medical University), Zhixuan Zhang(Soochow University), Chunmeng Wang(Chinese PLA General Hospital), Wei Tang(Peking University), Zhaoxuan Wang(Northeast Normal University), Qingming Yang(Chinese PLA General Hospital), Jinhong Shi(Chinese PLA General Hospital), Yuting Yi, Pengfei Yuan(Hefei University of Technology), Wenjuan Zheng(Peking University), Kuiying Ma, Ling Yang(Fraternal Order of Eagles), Xufen Zheng(Shanghai Institute of Nutrition and Health)
Cited by 30
Related Papers
LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b
|Journal of Translational Medicine|2015|660
Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR–Cas9 library
|Nature Biotechnology|2016|438
New development in CAR-T cell therapy
|Journal of Hematology & Oncology|2017|409
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
|Journal of Hematology & Oncology|2018|395
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
|Journal of Hematology & Oncology|2020|320